Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
(NASDAQ:VERV), BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 […]